CR

Carlo Rizzuto

Managing Director at Versant Ventures

New York, New York

Invests in

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Pharmaceutical Industry
Lifesciences
Medical Devices
Strategy
Business Strategy
Strategic Planning
Management Consulting
Product Development
Biotechnology
R&D
Marketing Strategy
Business Planning
Molecular Biology
Venture Capital
Drug Development
Business Development
Cross-functional Team Leadership
Life Sciences

Education

Work Experience

  • Managing Director

    2022

  • Partner

    2012 - 2022

    Director, Graphite Bio (GRPH) Director, Century Therapeutics (IPSC) Director, Jnana Therapeutics Director, FirstLight Bio Director, 858 Therapeutics Director, Stablix Director, Nested Therapeutics Director, Pandion Therapeutics (PAND, acquired) Director, Venatorx (2017-2022) Founding CEO, Kyras Therapeutics (2015-2017) Chief Business Officer, Anokion (2014-2017)

Highline Therapeutics

2015 - 2022

  • CEO

    2015 - 2022

    Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.

2010 - 2012

  • Global Program Team Director

    2010 - 2012

    Lead global, cross-functional team developing intelligent medicines by integrating electronics and pharmaceuticals to enable remote patient monitoring/e-health applications

Novartis International AG

2010 - 2010

  • Assistant to the CEO

    2010 - 2010

2009 - 2010

  • Assistant to CEO - Pharmaceuticals

    2009 - 2010

2002 - 2008

  • Associate Principal

    2002 - 2008

engeneOS

2000 - 2002

  • Business Development Manager

    2000 - 2002